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Abstract 
EYA2 encodes a co-activator for the SIX family of 
homeobox transcription factors. The SIX/EYA 
transcriptional complex plays important roles in 
organogenesis, promoting the proliferation and 
survival of progenitor cells. Abnormal re-expression 
of EYA2 in adult tissue promotes tumorigenesis and 
metastasis in multiple tumor types. In addition to its 
role as a co-activator, the EYA Domain (ED) of 
EYA2 contains a unique HAD family Tyr 
phosphatase activity, which plays a role in ERβ 
specific anti-tumor activity in breast cancer. The 
EYA2 Tyr phosphatase can also dephosphorylate 
H2AX, potentially playing a role in DNA damage 
repair. The N-terminal region of EYA2 also contains 
a Ser/Thr phosphatase activity, which may regulate 
the innate immune response. 
Keywords: Transcriptional co-activator, 
phosphatase, organogenesis, oncogenesis. 
Identity 
Other names: EAB1 
HGNC (Hugo): EYA2 
Location : 20q13.12 
DNA/RNA 
Description 
EYA2 gene is located at 20q13 (a frequently 
amplified region (Zhang et al., 2005)) and has 16 
exons. 
Transcription 
The transcript of EYA2 gene is 2702 bp long. 
Coding sequence of EYA2 starts at the 375th bp and 
ends at the 1991st bp of the mRNA. 
Pseudogene 
No pseudogene has been reported for EYA2. 
Protein 
Description 
The EYA2 gene encodes a 538 amino acid protein 
with a predicted molecular weight of 59 kDa.  
It is composed of a flexible N-terminal region and a 
highly conserved C-terminal EYA domain (ED). 
The N-terminal region is poorly conserved among 
EYA family members (EYA1, EYA2, EYA3 and 
EYA4) and the lengths of the N-terminal region in 
EYA2 vary amongst species.  
The N-terminal region contains a Pro/Ser/Thr rich 
transactivation domain that is responsible for 
activating SIX-mediated transcription (Xu et al., 
1997a; Ohto et al., 1999).  
The N-terminal region of all mouse EYA family 
members have been shown to possess Ser/Thr 
phosphatase activity, and this activity of EYA4 was 
shown to play a role in regulating the innate immune 
response (Okabe et al., 2009; Sano and Nagata, 
2011). 
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A schematic representation of the EYA2 protein that contains a flexible N-terminal region and a highly conserved C-terminal EYA 
domain (ED). 
The highly conserved C-terminal ED mediates the 
interaction between EYA2 and its protein partners, 
including SIX1 (Patrick et al., 2013). The ED of 
EYA2 also contains Mg2+-dependent Tyr 
phosphatase activity (Krishnan et al., 2009; Yuan et 
al., 2014). Crystal structures of both the ED of 
human EYA2 and the SIX1/EYA2 ED complex have 
been determined, providing detailed structural 
information for the C-terminal half of EYA2 (Jung 
et al., 2010; Patrick et al., 2013). 
Expression 
To date, there has been no investigation of EYA2 
protein levels in different developmental stages or 
tissues, but the mRNA transcripts of EYA2 have 
been examined by Northern blot, real time RT-PCR 
or in situ hybridization.  
In general, EYA2 expression is high and widespread 
in embryo and is low and limited in adult tissues. 
In situ hybridization in mouse embryo detected Eya2 
in facioacoustic ganglionic complex, epibranchial 
placodes, nasal placodes, somites, branchial arch 
ectoderm, the trigeminal, dorsal root ganglia, cranial 
placodes, central nervous system, neural retina, 
sclera, optic nerve sheath (Xu et al., 1997b), and the 
tendons and ligaments of the limb (Xu et al., 1997a). 
EYA2 expression in limb displayed a pattern similar 
to that of SIX1. 
In newborn mice, EYA2 was detected using 
Northern blot in the eye, brain, and lung at high 
levels, but was not detected in the skin, liver, 
intestine, and kidney (Duncan et al., 1997). 
In adult mice, EYA2 mRNA remains at high levels 
in the eye lens, and is decreased in the lung and brain 
based on Northern blot analyses (Duncan et al., 
1997). EYA2 mRNA can also be detected in thymus 
and uterus (Zimmerman et al., 1997). 
In adult humans, EYA2 was predominantly observed 
in muscle, and at lower levels in kidney, placenta, 
brain, and pancreas based on Northern blot analyses 
(Duncan et al., 1997). RT-PCR revealed EYA2 
mRNAs in human testis, colon, thymus, thyroid and 
prostate (Zhang et al., 2005). 
Localisation 
EYA2 is localized in both the nucleus and cytoplasm 
(Ohto et al., 1999; Fougerousse et al., 2002; 
Farabaugh et al., 2012). The SIX proteins actively 
translocate EYAs into the nucleus for SIX/EYA 
mediated transcriptional activation (Ohto et al., 
1999). 
Function 
EYA2 functions both as a transcriptional co-
activator and a protein phosphatase. Although EYA2 
is best known for its role as a co-activator for the SIX 
family transcription factors, it can also form 
complexes with PAX6 (Xu et al., 1997b) and 
DACHSHUND (Heanue et al., 1999) to mediate 
transcriptional activation of downstream genes. SIX 
proteins promote cell proliferation and survival 
(Ford et al., 1998; Li et al., 2002; Li et al., 2003; Del 
Bene et al., 2004; Coletta et al., 2004; Zou et al., 
2004; Zou et al., 2006), likely by collaborating with 
EYA proteins including EYA2. EYA2 is involved in 
the development of eye, kidney, ear, heart (Duncan 
et al., 1997), limb (Xu et al., 1997a), and cranial 
placodes (Xu et al., 1997b). An Eya2 transgene can 
rescue the eyeless phenotype in a fly eya mutant, 
implicating EYA2 as an important regulator of eye 
development (Bui et al., 2000). EYA2 also controls 
muscle development during organogenesis by 
regulating the expression of c-MYC, GDNF, and 
muscle determination genes such as MYOD, MRF4, 
and MYOG (Fougerousse et al., 2002; Grifone et al., 
2007). EYA2 may also activate novel anti-
hypertrophic signaling pathways to prevent cardiac 
hypertrophy and heart failure (Lee et al., 2009). 
The EYA domain of EYA2 contains a HAD family 
Tyr phosphatase activity, which dephosphorylates 
the Y36 residue of ERβ (Yuan et al., 2014). Since 
phosphorylated Y36 is required for ERβ to recruit 
co-activators to its target promoters and subsequent 
activation of antitumor transcriptional pathways, 
EYA2-mediated dephosphorylation of Y36 
counteracts ERβ dependent antitumor activity in 
breast cancer cell culture and mouse xenograft 
models (Yuan et al., 2014). In addition, the Tyr 
phosphatase activity of EYA3 was shown to 
dephosphorylate H2AX and leads cells to the DNA 
repair instead of apoptosis pathway upon DNA 
damage (Cook et al., 2009). Although EYA2 is also 
able to dephosphorylate H2AX (Krishnan et al., 
2009), its direct role in DNA damage response has 
not been experimentally proven. Furthermore, the N-
terminal region of EYA2 contains a Ser/Thr 
phosphatase activity, similar to EYA4 whose 
Ser/Thr phosphatase activity has been shown to play 
a role in innate immune response (Okabe et al., 
2009). 
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Homology 
The EYA Domain (ED) of human EYA2 has 64% 
sequence identity (83% similarity) with Drosophila 
EYA (Tadjuidje and Hegde, 2013), and 99% 
sequence identity (97% similarity) with mouse 
EYA2 (calculated by Clustal W). Within the human 
EYA family, EYA2 displays 83% sequence identity 
(92% similarity) with EYA1; 68% sequence identity 
(83% similarity) with EYA3; and 80% sequence 
identity (91% similarity) with EYA4 (Tadjuidje and 
Hegde, 2013). 
Mutations 
Germinal 
No EYA2 mutants were reported. 
Somatic 
A number of genomic variants in normal individuals 
(Redon et al., 2006; Mills et al., 2006; de Smith et 
al., 2007; McCarroll et al., 2008; Park et al., 2010; 
Teague et al., 2010; Xu et al., 2011; Genomes Project 
et al., 2012; Wong et al., 2013) and cancer patients 
(COSMIC (Forbes et al., 2008) and TCGA (Cerami 
et al., 2012; Gao et al., 2013)) have been reported, 
although the correlation between these variants and 
any disease phenotypes is not yet clear. In addition, 
EYA2 is amplified in 14.8% of ovarian carcinomas 
and its protein product was detected in 93.6% of 
ovarian cancer specimens (Zhang et al., 2005). 
Aberrant overexpression of EYA2 is observed in 
breast cancer (Zhang et al., 2005; Farabaugh et al., 
2012), lung adenocarcinoma (Zhang et al., 2005; 
Guo et al., 2009), prostate cancer (Zhang et al., 
2005), desmoid tumors (Bacac et al., 2006), and 
urinary tract cancers (Zhang et al., 2005). The 
Oncomine database reveals that EYA2 is 
significantly overexpressed in multiple other tumor 
types, including infiltrating bladder urothelial 
carcinoma, superficial bladder cancer, glioblastoma, 
high grade squamous intraepithelial neoplasia, 
cervical cancer, and parathyroid gland adenoma 
(Patrick et al., 2013). On the other hand, decreased 
level of EYA2 by silencing methylations has been 
reported in colorectal cancers (Zou et al., 2007) and 
pancreatic cancer (Vincent et al., 2014). 
Implicated in 
Various cancers 
Note 
EYA2 is heavily implicated in breast tumorigenesis 
and metastasis. Knock down of EYA2 in SIX1-
overexpressing MCF7 cells inhibits the ability of 
SIX1 to induce TGF-β signaling, epithelial-
mesenchymal transition (EMT), and tumor  
initiating cell (TIC) characteristics, properties that 
are all associated with SIX1-induced tumorigenesis 
and metastasis (Farabaugh et al., 2012). Examination 
of the Wang and Van de Vijver public breast cancer 
microarray datasets demonstrated that over-
expression of SIX1 and EYA2 together (but not 
either gene alone) is significantly associated with 
shortened time to relapse and metastasis and 
shortened survival (Farabaugh et al., 2012). 
Disruption of the SIX1-EYA2 interaction inhibits 
SIX1-EYA2 mediated breast tumor metastasis in 
mouse model (Patrick et al., 2013).  
EYA2 has also been shown to dephosphorylate Y36 
of ERβ and reduces ERβ-mediated growth inhibition 
of breast cancer cells (Yuan et al., 2014).  
In addition, high SIX1/EYA2 expression correlates 
with decreased survival in large cell lung carcinoma 
and more advanced stage in ovarian serous 
adenocarcinoma (Patrick et al., 2013). 
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